Portfolio / Alveron

Alveron.gif

Alveron Pharma is developing a unique coagulation platform technology with the world’s first cyclodextrin-based anticoagulant reversal drug.

Alveron Pharma's proprietary cyclodextrin-based compounds accelerate, but not initiate, coagulation via a unique mechanism. These compounds can therefore be used as systemic anti-bleeding agents, and our lead program is focused on developing a truly universal anticoagulant reversal agent.

Team member:  Michel Briejer

Team member: Michel Briejer

 

Company: ALVERON

Fund: II

Status: Active

Website

 
logo therapeutics.jpg

Technology:
Therapeutics